Hosted on MSN1mon
Stifel maintains $28 target on Phathom Pharmaceuticals stockFriday - Stifel analysts have maintained a Buy rating ... is optimistic that Voquezna, in its bottle format, will be granted the same 10-year exclusivity currently enjoyed by the combo packs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results